Vimentin is another mesenchymal marker for EMT, and several reports have demonstrated that vimentin is overexpressed in cancers, such as gastric cancer [73], breast cancer [74], and prostate cancer [75], which is associated with invasive phenotype and poor prognosis. This evidence concerns the gene VIM and breast cancer.